GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Valacyclovir

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The source HD summary does not distinguish indications. It must not override the indication-specific one-dose labialis or suppressive schedules without current-label review.

Check source scope before reading a dose

UCSF - valacyclovir: indication-specific oral dosing

Product / population
Adults; valacyclovir oral systemic formulations.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional

UCSF - valacyclovir: indication-specific oral dosing

Open original reference

UCSF Infectious Diseases Management Program · Adults; valacyclovir oral systemic formulations.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Choose the indication rather than applying a zoster regimen to HSV.

Initial orolabial/genital HSV or recurrent episode with HIV - oral
CrCl, mL/minSource-specific dose / instruction
>=501000 mg every 12 hours
30-491000 mg every 12 hours
10-291000 mg every 24 hours
<10500 mg every 24 hours
HSV suppression or separately listed recurrent-episode regimen - oral
CrCl, mL/minSource-specific dose / instruction
>=50500 mg every 12 hours
30-49500 mg every 12 hours
10-29500 mg every 24 hours
<10500 mg every 24 hours
Primary varicella or herpes zoster - oral
CrCl, mL/minSource-specific dose / instruction
>=501000 mg every 8 hours
30-491000 mg every 12 hours
10-291000 mg every 24 hours
<10500 mg every 24 hours
Dialysis guidance - separate source-specific schedules
Valacyclovir dialysis
Dialysis setting / indicationSource-specific schedule
IHD500 mg orally each evening
Continuous HDInsufficient data; obtain ID guidance
Read the retained text before reformatting

Adult CrCl bands are >=50 / 30-49 / 10-29 / <10 mL/min. For initial orolabial/genital HSV or recurrent-episode treatment with HIV, doses are respectively 1000 / 1000 / 1000 / 500 mg, at intervals of 12 / 12 / 24 / 24 hours. For HSV suppression or the separately listed recurrent-episode regimen, use 500 mg every 12 / 12 / 24 / 24 hours. Primary varicella or herpes zoster: 1000 mg every 8 / 12 / 24 hours, then 500 mg daily in the lowest band.

The intermittent-HD table lists 500 mg orally each evening. Continuous-HD data are insufficient; obtain ID guidance. Select the indication rather than transferring a zoster dose to HSV.

RDM30-025-valacyclovir-1 · Source locator: UCSF - valacyclovir: indication-specific oral dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/valacyclovir
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
000714ac8b13813420508a7b8f258acfa9c826b508893a219ddeff7e28903840

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=valacyclovir&s1=RDM30-025-valacyclovir&h1=db86605fffc610a057d9315a1726a4b5bd5f306d7a343beaf622c99df9512f45